Mirati Therapeutics Inc
Change company Symbol lookup
Select an option...
MRTX Mirati Therapeutics Inc
SIRC Solar Integrated Roofing Corp
CHSTY China High Speed Transmission Equipment Group Co Ltd
TTMZF Datable Technology Corp
WVFC W V S Financial Corp
WHLM Wilhelmina International Inc
SON Sonoco Products Co
VIRX Viracta Therapeutics Inc
PFS Provident Financial Services Inc
LPLA LPL Financial Holdings Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Mirati Therapeutics Inc is a United States-based clinical-stage biotechnology company that is focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. The Company is using its scientific expertise to develop novel solutions in two registration-enabling programs: adagrasib (MRTX849), an investigational small molecule, potent and selective KRASG12C inhibitor, as monotherapy and in combination with other agents, and sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies. The Company is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRASG12D inhibitor, MRTX1719, an investigational PRMT5 inhibitor, and other oncology discovery programs.

Premarket

Last Trade
Delayed
$73.74
2.22 (3.10%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$71.52
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
214

10-day average volume:
2,168,695
214

STOCKHOLDER ALERT: The M&A Class Action Firm Launches Merger Inquiry - RFP, SBTX, GBT, EVOP

2:26 pm ET September 24, 2022 (PR Newswire) Print

Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:

-- Resolute Forest Products Inc. (RFP), relating to its proposed acquisition by The Paper Excellence Group, via Domtar Corp. Under the terms of the agreement, RFP shareholders will receive $20.50 in cash plus one Contingent Value Right per share they own. Click here for more information: https://www.monteverdelaw.com/case/resolute-forest-products-inc. It is free and there is no cost or obligation to you.

-- Silverback Therapeutics, Inc. (SBTX), relating to its proposed merger with ARS Pharmaceuticals, Inc. Under the terms of the agreement, SBTX equity holders are expected to own approximately 37% of the combined company. Click here for more information: https://www.monteverdelaw.com/case/silverback-therapeutics-inc. It is free and there is no cost or obligation to you.

-- Global Blood Therapeutics, Inc. (GBT), relating to its proposed acquisition by Pfizer Inc. Under the terms of the agreement, GBT shareholders are expected to receive $68.50 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/global-blood-therapeutics-inc. It is free and there is no cost or obligation to you.

-- EVO Payments, Inc. (EVOP), relating to its proposed acquisition by Global Payments Inc. Under the terms of the merger, EVOP shareholders are expected to receive $34.00 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/evo-payments-inc. It is free and there is no cost or obligation to you.

https://mma.prnewswire.com/media/443626/Monteverde_Associates_PC_Logo.jpg

About Monteverde & Associates PCWe are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing. We were listed in the Top 50 in the 2018-2021 ISS Securities Class Action Services Report. Our lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions. Mr. Monteverde is recognized by Super Lawyers in 2013 and 2017-2019 as a Rising Star and in 2022 as a Super Lawyer in Securities Litigation. He has also been selected by Martindale-Hubbell as a 2017-2021 Top Rated Lawyer. Our firm's recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, in 2019 we recovered or secured six cash common funds for shareholders in mergers & acquisitions class action cases.

If you own common stock in any of the above listed companies and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.

Contact:Juan E. Monteverde, Esq.MONTEVERDE & ASSOCIATES PCThe Empire State Building350 Fifth Ave. Suite 4405New York, NY 10118United States of Americajmonteverde@monteverdelaw.comTel: (212) 971-1341

Attorney Advertising. (C) 2022 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

https://c212.net/c/img/favicon.png?sn=DC83296&sd=2022-09-24

View original content to download multimedia:https://www.prnewswire.com/news-releases/stockholder-alert-the-ma-class-action-firm-launches-merger-inquiry---rfp-sbtx-gbt-evop-301632568.html

SOURCE Monteverde & Associates PC

https://rt.prnewswire.com/rt.gif?NewsItemId=DC83296&Transmission_Id=202209241426PR_NEWS_USPR_____DC83296&DateId=20220924

comtex tracking

COMTEX_415201162/1005/2022-09-24T14:26:10

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.